Marco Floridia

Summary

Affiliation: Istituto Superiore di Sanit
Country: Italy

Publications

  1. ncbi Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs
    Marco Floridia
    Istituto Superiore di Sanita, Rome, Italy
    Antivir Ther 11:941-6. 2006
  2. doi Voluntary pregnancy termination among women with HIV in the HAART era (2002-2008): a case series from a national study
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Care 22:50-3. 2010
  3. ncbi Lipid profile during pregnancy in HIV-infected women
    M Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome
    HIV Clin Trials 7:184-93. 2006
  4. doi Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    HIV Clin Trials 11:303-11. 2010
  5. pmc Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy
    M Floridia
    Istituto Superiore di Sanità ISS, Department of Drug Evaluation and Research, Rome, Italy
    Epidemiol Infect 134:1120-7. 2006
  6. ncbi Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<5
    M Floridia
    Istituto Superiore di Sanita, Rome, Italy
    HIV Med 5:1-10. 2004
  7. doi Declining HCV seroprevalence in pregnant women with HIV
    M Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    Epidemiol Infect 138:1317-21. 2010
  8. ncbi Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality
    M Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
    BJOG 114:896-900. 2007
  9. ncbi Plasma lipid profile in pregnant women with HIV receiving nevirapine
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    AIDS Patient Care STDS 23:147-52. 2009
  10. ncbi HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy
    Enrica Tamburrini
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 13:519-27. 2008

Detail Information

Publications40

  1. ncbi Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs
    Marco Floridia
    Istituto Superiore di Sanita, Rome, Italy
    Antivir Ther 11:941-6. 2006
    ..Therapeutic changes during pregnancy were also analysed...
  2. doi Voluntary pregnancy termination among women with HIV in the HAART era (2002-2008): a case series from a national study
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Care 22:50-3. 2010
    ..Women with low CD4 counts and those with an HIV-infected partner represent two groups that should receive particular attention in preventive strategies...
  3. ncbi Lipid profile during pregnancy in HIV-infected women
    M Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome
    HIV Clin Trials 7:184-93. 2006
    ..We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study...
  4. doi Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    HIV Clin Trials 11:303-11. 2010
    ..To investigate the risk factors for an HIV-1 RNA plasma viral load above 400 copies/mL in the third trimester of pregnancy...
  5. pmc Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy
    M Floridia
    Istituto Superiore di Sanità ISS, Department of Drug Evaluation and Research, Rome, Italy
    Epidemiol Infect 134:1120-7. 2006
    ..This suggests a good HIV detection during pregnancy, but also the need to reinforce HIV testing strategies among women of childbearing age. We identified some determinants which may be considered for intervention measures...
  6. ncbi Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<5
    M Floridia
    Istituto Superiore di Sanita, Rome, Italy
    HIV Med 5:1-10. 2004
    ....
  7. doi Declining HCV seroprevalence in pregnant women with HIV
    M Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    Epidemiol Infect 138:1317-21. 2010
    ..03-0.29]. Previous IDU was the stronger determinant of HCV co-infection in pregnant women with HIV (aOR 30.9, 95% CI 18.8-51.1). The observed trend is expected to translate into a reduced number of cases of vertical HCV transmission...
  8. ncbi Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality
    M Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
    BJOG 114:896-900. 2007
    ..Specific interventions, however, are needed to increase the rates of counselling and HIV testing before pregnancy in foreign women...
  9. ncbi Plasma lipid profile in pregnant women with HIV receiving nevirapine
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    AIDS Patient Care STDS 23:147-52. 2009
    ..Further studies should assess whether this effect is due to an intrinsic activity of nevirapine and define the potential mechanisms involved...
  10. ncbi HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy
    Enrica Tamburrini
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 13:519-27. 2008
    ..In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations...
  11. doi Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes
    Silvia Baroncelli
    Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
    AIDS Patient Care STDS 23:513-20. 2009
    ..Constant improvements in the rates of HIV suppression were observed, probably driven by the adoption of stronger and more effective regimens and by the increasing options available for combination treatment...
  12. pmc Pregnancy outcomes in women with advanced HIV infection in Italy
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Patient Care STDS 25:639-45. 2011
    ..During postpartum care, women with more advanced HIV infection should receive particular care to prevent loss of virologic suppression...
  13. pmc Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection
    Liliana Elena Weimer
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    J Antimicrob Chemother 68:193-9. 2013
    ....
  14. doi Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAART
    Carmela Pinnetti
    Department of Infectious Diseases, Catholic University, Rome, Italy
    HIV Clin Trials 10:403-12. 2009
    ..A prospective study was designed to evaluate the prevalence and determinants of glucose metabolism abnormalities (GMAs) among HIV-1-infected pregnant women receiving highly active antiretroviral therapy (HAART)...
  15. doi Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome Department of Pharmacology, Fondazione IRCCS, Policlinico San Matteo, Pavia Department of Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma Division of Infectious Disease, University of Bari, Bari Division of Infectious Diseases, Department of Experimental Medicine, University of Perugia, Perugia Infectious Diseases Unit, Pistoia Hospital, Pistoia Infectious Disease Unit, Pescara General Hospital, Pescara Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, S Orsola Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna Clinic of Infectious Diseases, Ospedali Riuniti, Marche Polytechnic University, Ancona and Department of Infectious Diseases, S Anna Hospital, Ferrara, Italy
    Ther Drug Monit 35:785-90. 2013
    ..There is no consensus on darunavir (DRV) target levels in plasma for clinical use, and information about variability in plasma concentrations is limited...
  16. doi Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    J Antimicrob Chemother 69:1377-84. 2014
    ..Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited...
  17. doi Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens
    Carmela Pinnetti
    Department of Infectious Diseases, Catholic University, Rome, Italy
    J Infect 63:144-50. 2011
    ..Although zidovudine-free regimens are increasingly used in pregnancy, their haematological effects in mothers and newborns are incompletely defined...
  18. doi Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy
    Ther Drug Monit 30:604-10. 2008
    ..Subtherapeutic predose concentrations among HIV-infected pregnant women were more commonly found with NVP than with protease inhibitors. LPV administration was associated with the best viral load suppression...
  19. ncbi Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected women
    Marco Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome
    AIDS 20:944-7. 2006
    ..Protease inhibitor treatment was also independently associated with hypertriglyceridemia...
  20. doi Brief Report: Consequences of Presentation With Advanced HIV Disease in Pregnancy: Data From a National Study in Italy
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy Department of Infectious Diseases, Catholic University, Rome, Italy Department of Obstetrics and Neonatology, Città della Salute e della Scienza Hospital, and Universiy of Turin, Turin, Italy Department of Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy Department of Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma, Italy Department of Obstetrics and Gynaecology, Luigi Sacco Hospital and University of Milan, Milan, Italy Department of Obstetrics and Gynaecology, DMSD San Paolo Hospital Medical School, University of Milan, Milan, Italy Department of Obstetrics and Gynaecology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy INMI Lazzaro Spallanzani, Rome, Italy Department of Obstetrics and Gynaecology, City Hospital, Prato, Italy and Operative Unit of Infectious Disease, Hospital of Macerata, Macerata, Italy
    J Acquir Immune Defic Syndr 70:452-5. 2015
    ..Early preterm delivery (<32 weeks) was significantly more frequent with low CD4 (6.2% vs. 1.4%, P = 0.015). An earlier access to HIV testing, particularly among immigrants of African origin, can prevent severe HIV-related morbidity. ..
  21. doi Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment
    Silvia Baroncelli
    1 Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Res Hum Retroviruses 31:673-8. 2015
    ..Women with high levels of HIV-RNA in early pregnancy and those who have concomitant HCV infection should be considered at higher risk of having quantifiable HIV-RNA at the end of pregnancy...
  22. pmc Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens
    Silvia Baroncelli
    1 Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Res Hum Retroviruses 31:71-7. 2015
    ..The potential influence of the interval between HIV diagnosis and initiation of treatment should be confirmed in subjects with a known date of seroconversion...
  23. doi Pregnancy outcomes in HIV-infected women of advanced maternal age
    Giuseppina Liuzzi
    I N M I Lazzaro Spallanzani, Rome, Italy
    HIV Clin Trials 14:110-9. 2013
    ..There is limited information on pregnancy outcomes in women with HIV who are of a more advanced maternal age...
  24. pmc Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease
    Antonella Esposito
    Dpt, of Clinical Medicine, Sapienza University of Rome, Rome, Italy
    BMC Infect Dis 11:341. 2011
    ..The optimal therapeutic strategies for patients presenting with advanced disease at HIV-1 diagnosis are as yet incompletely defined...
  25. doi Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIV
    Marco Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
    HIV Clin Trials 9:287-97. 2008
    ..Few studies have assessed the determinants of birthweight in newborns from HIV-positive mothers in analyses that adjusted for different gestational age at delivery...
  26. ncbi A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection
    S Vella
    Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    Antivir Ther 1:129-40. 1996
    ..The combination of drugs with different mechanisms of action represents an advance in the treatment of HIV infection...
  27. doi Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    Ann Pharmacother 44:838-43. 2010
    ..The safety and efficacy of both drugs have been investigated, but there is no information on possible pharmacokinetic interactions between these 2 drugs in clinical practice...
  28. doi Relationship between health-related quality of life measures and high HIV viral load in HIV-infected triple-class-experienced patients
    Raffaella Bucciardini
    Istituto Superiore di Sanita, Rome, Italy
    HIV Clin Trials 15:176-83. 2014
    ..Although the association of HIV RNA and CD4 cell count with clinical HIV progression has been well established, the relation between these markers and HRQoL measures is still unclear...
  29. ncbi Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy
    Raffaella Bucciardini
    Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Res Hum Retroviruses 23:1215-22. 2007
    ....
  30. pmc Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    J Antimicrob Chemother 67:1479-85. 2012
    ..To evaluate the evolution of HIV-1 coreceptor tropism in proviral DNA of patients during maraviroc-based therapy...
  31. doi Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
    J Med Virol 83:551-6. 2011
    ..The distinct effects of these two pathways should be considered...
  32. ncbi Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients
    R Bucciardini
    Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    AIDS 14:2567-74. 2000
    ....
  33. ncbi Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization
    Alessandra Fantauzzi
    Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy
    New Microbiol 38:531-40. 2015
    ..Switching to ABC/3TC was effective and safe. Inflammatory markers remained low in both groups. Some changes in metabolic, kidney and cytokine profiles were apparently specific for baseline cART treatment. ..
  34. doi Gender differences in the treatment of HIV infection
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Pharmacol Res 58:173-82. 2008
    ..To obtain this goal, specific studies should be designed and females' participation in both cohort studies and clinical trials should be promoted...
  35. doi Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants
    Giuseppe Liotta
    aDepartment of Biomedicine and Prevention, University of Rome Tor VergatabDepartment of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, ItalycDREAM Program, Community of S Egidio, Blantyre, MalawidLUMSA University, Rome, Italy
    AIDS 30:525-7. 2016
    ..Growth indices were similar in the two cohorts at one and 6 months but were significantly better in the first group at 12 months, suggesting no negative effect of tenofovir and a significant benefit of extended breastfeeding. ..
  36. doi Percentage and determinants of missed HIV testing in pregnancy: a survey of women delivering in the Lazio region, Italy
    Sabrina Valle
    a Laziosanità, Agenzia di Sanità Pubblica, Rome, Italy
    AIDS Care 26:899-906. 2014
    ..Strategies to increase routine testing may include the adoption of an opt-out approach. Finally, availability of rapid HIV testing in the delivery room should be encouraged...
  37. ncbi HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial
    M Floridia
    ISS IP 1 Study Group, Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    HIV Med 3:75-84. 2002
    ..It is, however, uncertain for most of the AIDS defining conditions whether this threshold can be considered equally safe in patients with a previously very low CD4 nadir...
  38. doi Epidemiological and clinical features of pregnant women with HIV: a 21-year perspective from a highly specialized regional center in southern Italy
    Pasquale Martinelli
    Department of Gynecology and Obstetrics, Centre for STD and HIV AIDS in Obstetrics and Gynecology, University of Naples Federico II, Napoli, Italy
    HIV Clin Trials 9:36-42. 2008
    ..To analyze the changes over two decades in HIV-infected pregnant women followed at a highly specialized regional center for antenatal care in southern Italy...
  39. ncbi Pregnancy and HIV infection: A european consensus on management
    Oriol Coll
    Hospital Clinic, University of Barcelona, Spain
    AIDS 16:S1-18. 2002
  40. ncbi Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania
    Claudio Blè
    Department of Infectious Diseases, S M Annunziata Hospital, ASL, Florence, Italy
    Acta Paediatr 96:1090-4. 2007